Inclusion of pregnant and breastfeeding women in research - efforts and initiatives

Sílvia M. Illamola, Christina Bucci-Rechtweg, Maged Costantine, Ekaterini Tsilou, Catherine M. Sherwin, Anne Zajicek

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethico-legal challenges that have remained entrenched in the post-diethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and -dynamic understanding of medication use in pregnancy.

Original languageEnglish (US)
JournalBritish Journal of Clinical Pharmacology
DOIs
StateAccepted/In press - 2017

Fingerprint

Breast Feeding
Pregnant Women
Pregnancy
Clinical Trials
Research
Lactation
Pharmacoepidemiology
Pharmacovigilance
Safety
Orphaned Children
Diethylstilbestrol
Thalidomide
Pharmaceutical Preparations
Lenses
Industry
Pharmacokinetics
Research Personnel
Therapeutics

Keywords

  • Breastfeeding
  • Clinical pharmacology
  • Drug utilization
  • Obstetric
  • Pregnancy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Cite this

Illamola, S. M., Bucci-Rechtweg, C., Costantine, M., Tsilou, E., Sherwin, C. M., & Zajicek, A. (Accepted/In press). Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.13438

Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. / Illamola, Sílvia M.; Bucci-Rechtweg, Christina; Costantine, Maged; Tsilou, Ekaterini; Sherwin, Catherine M.; Zajicek, Anne.

In: British Journal of Clinical Pharmacology, 2017.

Research output: Contribution to journalArticle

Illamola, Sílvia M. ; Bucci-Rechtweg, Christina ; Costantine, Maged ; Tsilou, Ekaterini ; Sherwin, Catherine M. ; Zajicek, Anne. / Inclusion of pregnant and breastfeeding women in research - efforts and initiatives. In: British Journal of Clinical Pharmacology. 2017.
@article{1d17c70f295641a896dfa3cf020cabfa,
title = "Inclusion of pregnant and breastfeeding women in research - efforts and initiatives",
abstract = "Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethico-legal challenges that have remained entrenched in the post-diethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and -dynamic understanding of medication use in pregnancy.",
keywords = "Breastfeeding, Clinical pharmacology, Drug utilization, Obstetric, Pregnancy",
author = "Illamola, {S{\'i}lvia M.} and Christina Bucci-Rechtweg and Maged Costantine and Ekaterini Tsilou and Sherwin, {Catherine M.} and Anne Zajicek",
year = "2017",
doi = "10.1111/bcp.13438",
language = "English (US)",
journal = "British Journal of Clinical Pharmacology",
issn = "0306-5251",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Inclusion of pregnant and breastfeeding women in research - efforts and initiatives

AU - Illamola, Sílvia M.

AU - Bucci-Rechtweg, Christina

AU - Costantine, Maged

AU - Tsilou, Ekaterini

AU - Sherwin, Catherine M.

AU - Zajicek, Anne

PY - 2017

Y1 - 2017

N2 - Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethico-legal challenges that have remained entrenched in the post-diethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and -dynamic understanding of medication use in pregnancy.

AB - Pregnant and breastfeeding women have been rendered therapeutic orphans as they have been historically excluded from clinical trials. Labelling for most approved drugs does not provide information about safety and efficacy during pregnancy. This lack of data is mainly due to ethico-legal challenges that have remained entrenched in the post-diethylstilbestrol and thalidomide era, and that have led to pregnancy being viewed in the clinical trial setting primarily through a pharmacovigilance lens. Policy considerations that encourage and/or require the inclusion of pregnant or lactating women in clinical trials may address the current lack of available information. However, there are additional pragmatic strategies, such the employment of pharmacometric tools and the introduction of innovative clinical trial designs, which could improve knowledge about the safety and efficacy of medication use during pregnancy and lactation. This paper provides a broad overview of the pharmacoepidemiology of drugs used during pregnancy and lactation, and offers recommendations for regulators and researchers in academia and industry to increase the available pharmacokinetic and -dynamic understanding of medication use in pregnancy.

KW - Breastfeeding

KW - Clinical pharmacology

KW - Drug utilization

KW - Obstetric

KW - Pregnancy

UR - http://www.scopus.com/inward/record.url?scp=85031719908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031719908&partnerID=8YFLogxK

U2 - 10.1111/bcp.13438

DO - 10.1111/bcp.13438

M3 - Article

C2 - 28925019

AN - SCOPUS:85031719908

JO - British Journal of Clinical Pharmacology

JF - British Journal of Clinical Pharmacology

SN - 0306-5251

ER -